Seprafilm®: proven to reduce postoperative adhesions1

Clinical benefits

Seprafilm is proven to reduce incidence, extent, and severity of postoperative adhesions and related complications.1 It has been studied in more than 4000 patients and in 40 published clinical reports.2

Reduction in reoperative adhesive small bowel obstruction (ASBO)

In a prospective, multicenter, randomized, controlled, blinded study of patients receiving Seprafilm during intestinal resection, Seprafilm reduced reoperation required for ASBO by 47% relative to untreated controls.3

Reduction in reoperative complexity

In a series of prospective clinical studies in which Seprafilm was placed at the initial procedure, Seprafilm reduced adhesions observed at subsequent surgery, resulting in

  • Fewer inadvertent injuries4
  • Less operative time5
  • Reduced blood loss5 
  • Easier ileostomy reversal4 

Reduction in adhesions and complexity at repeat C-Section

In a study of patients receiving Seprafilm at primary C-Section, Seprafilm significantly reduced adhesions, resulting in faster procedure and delivery times at repeat C-Sections.5

Reduction in incidence of early postoperative small bowel obstruction (EPSBO) in gastrointestinal surgery

In a retrospective analysis in which 184 patients treated with Seprafilm were compared with 183 patients in the control group, patients treated with Seprafilm showed 54% less incidence of EPSBO (P<0.05).6

Indication
Seprafilm® Adhesion Barrier is indicated for the reduction of post-surgical adhesions in patients undergoing abdominal or pelvic laparotomy.

Important Safety Information
Seprafilm should not be wrapped around an intestinal anastomosis as such usage may result in increased anastomotic leak related events, such as abscess or peritonitis. The safety and effectiveness of Seprafilm has not been established in combination with other adhesion prevention products and/or in surgical procedures not within the abdominopelvic cavity. The safety and effectiveness of Seprafilm has also not been evaluated in cases of pregnancy, malignancy, or frank infection. The type and frequency of adverse events reported are consistent with events typically seen following abdominopelvic surgery when used as directed.

Please see full prescribing information.

References

  1. Becker JM, Dayton MT, Fazio VW, et al. Prevention of postoperative abdominal adhesions by a sodium hyaluronate-based bioresorbable membrane: a prospective, randomized, double-blind multicenter study. J Am Coll Surg. 1996;183(4):297-306.
  2. Data on file, Genzyme Corp.
  3. Fazio VW, Cohen Z, Fleshman JW, et al. Reduction in adhesive small-bowel obstruction by Seprafilm Adhesion Barrier after intestinal resection. Dis Colon Rectum. 2005;49(1):1-11
  4. Tang C-L, Seow-Choen F, Fook-Chong S, Eu K-W. Bioresorbable adhesion barrier facilitates early closure of the defunctioning ileostomy after rectal excision: a prospective randomized trial. Dis Colon Rectum. 2003;46(9):1200-1207.
  5. Fushiki H, Ikoma T, Kobayashi H, Yoshimoto H. Efficacy of Seprafilm as an adhesion prevention barrier in cesarean sections. Obstet Gynecol Treatment. 2005;91(5):557-561.
  6. Mohri Y, Uchida K, Araki T, et al. Hyaluronic acid–carboxycellulose membrane (Seprafilm) reduces early postoperative small bowel obstruction in gastrointestinal surgery. Am Surg. 2005;71(10):861-863.

Applying Seprafilm

View a demonstration of common application techniques that may help when using Seprafilm.

Watch videos

Accommodate a wide range of abdominal and pelvic laparotomy surgeries with Seprafilm

Seprafilm has multiple configurations; find out which configuration is right for your practice.

Learn more